Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Hypertension, Hemodialysis

In brief

The purpose of this study is to examine the effects of the digibind drug on hemodialysis patients with high blood pressure. Digibind is used to treat toxicity from digoxin and digoxin-like molecules which may contribute to high blood pressure.

Key facts

Study ID

NCT00852787

Run by

National Institute on Aging (NIA)

People needed

30

Starts

2009-04-01

Expected to finish

2012-05-01

Last updated by the study team

2012-05-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18-75 years of age
• On hemodialysis with predialysis BP > 150/90 but ≤ 180/110
• On at least one anti-hypertensive medication for 6 consecutive readings
• Able to have blood pressure measured in an arm
• Women of child bearing potential must not be pregnant; must use contraception during the study and for one month after the study
• Receiving adequate dialysis (KT/V > 1.2)
• Compliant with the dialysis schedule and duration

You may not qualify if…

• Pregnant or nursing women
• Arm blood pressure is not possible to obtain
• Currently on digitalis
• On any Digibind-type product in the past
• History of allergies to antibiotics
• History of asthma
• Medical or psychiatric disorders which are unstable or which might interfere with study assessments or safe participation in the study
• History of use of, or evidence of need for, digitalis-like products
• Inability to understand or provide informed consent

Where it is running

• University of Toledo Medical Center — Toledo, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.